Merck KGaA Sticks With Structure, Eyes Smaller Healthcare Deals
There may be a trend towards spinning off business units but Merck continues to sees its three-pillar structure as providing the best protection from downturns in any individual segment.
You may also be interested in...
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
After a miserable third quarter the German group is cutting jobs and considering splitting up, but concrete decisions are thin on the ground.
The French drugmaker is significantly upping its R&D spend and exiting consumer care, a strategy CEO Paul Hudson has stoutly defended following a slump in the share price.